Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Almanza Huante

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|September 7, 2020
Comparison of Two Pediatric-Inspired Regimens to Hyper-CVAD in Hispanic Adolescents and Young Adults With Acute Lymphoblastic LeukemiaEmmanuel Almanza-Huante, Karla Espinosa-Bautista, Juan Rangel-Patiño, et al.
Leukemia & Lymphoma|August 9, 2021
Central nervous system (CNS) involvement has an adverse impact on survival in newly diagnosed adult acute lymphoblastic leukemia (ALL) assessed by flow cytometryRosana Daniela Córdova-Serrano, Emmanuel Almanza-Huante, Emmanuel Fernández-Sánchez, et al.
ACG Case Reports Journal|September 7, 2023
Gastric Myeloid SarcomaAbdullah S Shaikh, Emmanuel Almanza Huante, Mehran Taherian, et al.
Leukemia Research|February 21, 2023
PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemiaAlex Bataller, Kelly S Chien, Koji Sasaki, et al.
British Journal of Haematology|March 23, 2023
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumoursEmmanuel Almanza-Huante, Alex Bataller, Samuel Urrutia, et al.
Hemasphere|October 24, 2025
A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemiaWei-Ying Jen, Jennifer Croden, Emmanuel Almanza-Huante, et al.
Blood Advances|March 21, 2024
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasmAlex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
American Journal of Hematology|August 28, 2025
Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based TherapiesWei-Ying Jen, Sanam Loghavi, Alexandre Bazinet, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical Lymphoma, Myeloma & Leukemia|September 7, 2020
Comparison of Two Pediatric-Inspired Regimens to Hyper-CVAD in Hispanic Adolescents and Young Adults With Acute Lymphoblastic LeukemiaEmmanuel Almanza-Huante, Karla Espinosa-Bautista, Juan Rangel-Patiño, et al.
Leukemia & Lymphoma|August 9, 2021
Central nervous system (CNS) involvement has an adverse impact on survival in newly diagnosed adult acute lymphoblastic leukemia (ALL) assessed by flow cytometryRosana Daniela Córdova-Serrano, Emmanuel Almanza-Huante, Emmanuel Fernández-Sánchez, et al.
ACG Case Reports Journal|September 7, 2023
Gastric Myeloid SarcomaAbdullah S Shaikh, Emmanuel Almanza Huante, Mehran Taherian, et al.
Leukemia Research|February 21, 2023
PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemiaAlex Bataller, Kelly S Chien, Koji Sasaki, et al.
British Journal of Haematology|March 23, 2023
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumoursEmmanuel Almanza-Huante, Alex Bataller, Samuel Urrutia, et al.
Hemasphere|October 24, 2025
A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemiaWei-Ying Jen, Jennifer Croden, Emmanuel Almanza-Huante, et al.
Blood Advances|March 21, 2024
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasmAlex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
American Journal of Hematology|August 28, 2025
Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based TherapiesWei-Ying Jen, Sanam Loghavi, Alexandre Bazinet, et al.
Pageof 1